These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 24155971

  • 1. Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment.
    Lin SF, Lin JD, Chou TC, Huang YY, Wong RJ.
    PLoS One; 2013; 8(10):e77684. PubMed ID: 24155971
    [Abstract] [Full Text] [Related]

  • 2. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.
    Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ, Lee SJ.
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E253-61. PubMed ID: 25389633
    [Abstract] [Full Text] [Related]

  • 3. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
    Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ, Lee SJ.
    Endocrine; 2016 Feb; 51(2):274-82. PubMed ID: 26219406
    [Abstract] [Full Text] [Related]

  • 4. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
    Catalano MG, Pugliese M, Gargantini E, Grange C, Bussolati B, Asioli S, Bosco O, Poli R, Compagnone A, Bandino A, Mainini F, Fortunati N, Boccuzzi G.
    Int J Cancer; 2012 Feb 01; 130(3):694-704. PubMed ID: 21400508
    [Abstract] [Full Text] [Related]

  • 5. Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells.
    Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ, Lee SJ.
    J Endocrinol Invest; 2018 Jun 01; 41(6):677-689. PubMed ID: 29147952
    [Abstract] [Full Text] [Related]

  • 6. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS, Jung KA, Kim SM, Hong YS, Ryu MH, Jang SJ, Moon DH, Cho DH, Kim JC, Lee JS, Kim TW.
    Cancer Chemother Pharmacol; 2011 Aug 01; 68(2):389-98. PubMed ID: 21046105
    [Abstract] [Full Text] [Related]

  • 7. Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy.
    Lin SF, Huang YY, Lin JD, Chou TC, Hsueh C, Wong RJ.
    PLoS One; 2012 Aug 01; 7(10):e46726. PubMed ID: 23077520
    [Abstract] [Full Text] [Related]

  • 8. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies.
    Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, Sehested M, Lichenstein HS, Jeffers M.
    Mol Cancer Ther; 2006 Aug 01; 5(8):2086-95. PubMed ID: 16928830
    [Abstract] [Full Text] [Related]

  • 9. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101.
    Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, La Thangue NB, Brown R.
    Mol Cancer Ther; 2003 Aug 01; 2(8):721-8. PubMed ID: 12939461
    [Abstract] [Full Text] [Related]

  • 10. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
    Zhang L, Zhang Y, Mehta A, Boufraqech M, Davis S, Wang J, Tian Z, Yu Z, Boxer MB, Kiefer JA, Copland JA, Smallridge RC, Li Z, Shen M, Kebebew E.
    Oncotarget; 2015 Apr 20; 6(11):9073-85. PubMed ID: 25940539
    [Abstract] [Full Text] [Related]

  • 11. Evodiamine in combination with histone deacetylase inhibitors has synergistic cytotoxicity in thyroid carcinoma cells.
    Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Lee SJ.
    Endocrine; 2019 Jul 20; 65(1):110-120. PubMed ID: 31102069
    [Abstract] [Full Text] [Related]

  • 12. Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer.
    Chan D, Zheng Y, Tyner JW, Chng WJ, Chien WW, Gery S, Leong G, Braunstein GD, Koeffler HP.
    J Cancer Res Clin Oncol; 2013 Sep 20; 139(9):1507-14. PubMed ID: 23824064
    [Abstract] [Full Text] [Related]

  • 13. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
    Luong QT, O'Kelly J, Braunstein GD, Hershman JM, Koeffler HP.
    Clin Cancer Res; 2006 Sep 15; 12(18):5570-7. PubMed ID: 17000694
    [Abstract] [Full Text] [Related]

  • 14. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
    Hwang JJ, Kim YS, Kim T, Kim MJ, Jeong IG, Lee JH, Choi J, Jang S, Ro S, Kim CS.
    Invest New Drugs; 2012 Aug 15; 30(4):1434-42. PubMed ID: 21773733
    [Abstract] [Full Text] [Related]

  • 15. Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
    Lin WC, Hsu FS, Kuo KL, Liu SH, Shun CT, Shi CS, Chang HC, Tsai YC, Lin MC, Wu JT, Kuo Y, Chow PM, Liao SM, Yang SP, Hong JY, Huang KH.
    J Mol Med (Berl); 2018 Dec 15; 96(12):1307-1318. PubMed ID: 30288546
    [Abstract] [Full Text] [Related]

  • 16. The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines.
    Ma BB, Sung F, Tao Q, Poon FF, Lui VW, Yeo W, Chan SL, Chan AT.
    Invest New Drugs; 2010 Apr 15; 28(2):107-14. PubMed ID: 19172229
    [Abstract] [Full Text] [Related]

  • 17. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
    Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S.
    Br J Haematol; 2007 Nov 15; 139(3):385-97. PubMed ID: 17910628
    [Abstract] [Full Text] [Related]

  • 18. Antitumor Activity of Berberine by Activating Autophagy and Apoptosis in CAL-62 and BHT-101 Anaplastic Thyroid Carcinoma Cell Lines.
    Shi XZ, Zhao S, Wang Y, Wang MY, Su SW, Wu YZ, Xiong C.
    Drug Des Devel Ther; 2023 Nov 15; 17():1889-1906. PubMed ID: 37397788
    [Abstract] [Full Text] [Related]

  • 19. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C.
    Mol Cancer Ther; 2007 Jan 15; 6(1):37-50. PubMed ID: 17237265
    [Abstract] [Full Text] [Related]

  • 20. Histone Deacetylase Inhibitors and Anaplastic Thyroid Carcinoma.
    Spartalis E, Athanasiadis DI, Chrysikos D, Spartalis M, Boutzios G, Schizas D, Garmpis N, Damaskos C, Paschou SA, Ioannidis A, Tsourouflis G, Dimitroulis D, Nikiteas NI.
    Anticancer Res; 2019 Mar 15; 39(3):1119-1127. PubMed ID: 30842140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.